Efficacy of Dupilumab in the Prevention of Seasonal Exacerbations in Patients With and Without Evidence of an Allergic Asthma Phenotype

Abstract

Asthma exacerbations are subject to seasonal variability. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation in multiple diseases. The TRAVERSE open-label extension study (NCT02134028) evaluated long-term safety and tolerability of add-on dupilumab in patients with uncontrolled, moderate-to-severe asthma from the 52-week QUEST study (NCT02414854). This post-hoc analysis assessed long-term dupilumab efficacy in reducing seasonal asthma exacerbations in patients with/without evidence of an allergic phenotype.